APTITUDE HEALTH®

EPICS

EPICS CONGRESS COVERAGE: ASCO 2020 – FOCUS ON MELANOMA

June, 2020

BACKGROUND

EPICS

- On June 12, 2020, following the American Society of Clinical Oncology (ASCO) annual meeting, Aptitude Health brought together a group of scientists and clinical investigators with expertise in melanoma to attend the Emerging Paradigms in Care Series (EPICS) Congress Coverage meeting

- The goal of the expert panel was to critique and debate new evidence in melanoma and gain strategic insight into the most impactful abstracts from the ASCO meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

MEET THE EXPERTS . . .

EPICS

Jeffrey S. Weber, MD, PhD
Perlmutter Cancer Center NYU Langone
New York, NY, USA

Michael Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Washington, DC, USA

Alexander Eggermont, MD, PhD
Princess Maxima Center for Pediatric Oncology
Utrecht, The Netherlands

James Larkin, MD
The Royal Marsden
London, UK

Reinhard Dummer, MD
University Hospital of Zurich
Zurich, Switzerland

Caroline Robert, MD, PhD
Institute Gustave-Roussy
Paris, France

AGENDA

EPICS

Time (EST)	Topic	Speaker/Moderator
1.00 PM – 1.05 PM (5 min)	**Welcome and Introductions**	**Moderator: Jeffrey Weber, MD, PhD**
1.05 PM – 1.10 PM (5 min)	**Melanoma Adjuvant and Neoadjuvant Therapy**	Alexander Eggermont, MD, PhD
1.10 PM – 1.20 PM (10 min)	Discussion: Melanoma Adjuvant and Neoadjuvant Therapy	**Moderator: Reinhard Dummer, MD**
1.20 PM – 1.30 PM (10 min)	**Relapsed/Refractory Metastatic Melanoma**	Caroline Robert, MD, PhD
1.30 PM – 1.50 PM (20 min)	Discussion: Relapsed/Refractory Metastatic Melanoma	**Moderator: James Larkin, MD**
1.50 PM – 2.00 PM (10 min)	**Immunotherapy for Metastatic Melanoma**	Michael Atkins, MD
2.00 PM – 2.20 PM (20 min)	Discussion: Immunotherapy for Metastatic Melanoma	**Moderator: Caroline Robert, MD, PhD**
2.20 PM – 2.30 PM (10 min)	***BRAF*-Mutated Metastatic Melanoma**	James Larkin, MD/Reinhard Dummer, MD
2.30 PM – 2.50 PM (20 min)	Discussion: *BRAF*-Mutated Metastatic Melanoma	**Moderator: Michael Atkins, MD**
2.50 PM – 3.00 PM (10 min)	Summary and Closing Remarks	Jeffrey Weber, MD, PhD

APTITUDE HEALTH®

EPICS

Melanoma Adjuvant and Neoadjuvant Therapy

ALEXANDER EGGERMONT, MD, PHD

PRINCESS MAXIMA CENTER FOR PEDIATRIC ONCOLOGY

UTRECHT, THE NETHERLANDS

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: ABSTRACTS (1/4)

EPICS

- **10015:** Twenty-four month RFS and updated toxicity data from OpACIN-neo: A study to identify the

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: ABSTRACTS (2/4)

EPICS

- **10002:** First safety and efficacy results of PRADO: A phase II study of personalized response-

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: ABSTRACTS (3/4)

EPICS

- **10000:** Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma:

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: ABSTRACTS (4/4)

EPICS

- **10017:** Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: DISCUSSION (1/2)

EPICS

- Regarding the use of anti–PD-1 antibodies in the adjuvant setting for high-risk stage III melanoma

MELANOMA ADJUVANT AND NEOADJUVANT THERAPY: DISCUSSION (2/2)

EPICS

- Results from the PRADO extension cohort of the OpACIN trial signal a potential shift to come in the

APTITUDE HEALTH®

EPICS

Relapsed/Refractory Metastatic Melanoma

CAROLINE ROBERT, MD, PHD
INSTITUTE GUSTAVE-ROUSSY
PARIS, FRANCE

RELAPSED/REFRACTORY METASTATIC MELANOMA: ABSTRACTS (1/4)

EPICS

- **10004:** Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO)

RELAPSED/REFRACTORY METASTATIC MELANOMA: ABSTRACTS (2/4)

EPICS

- **10005:** Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with

RELAPSED/REFRACTORY METASTATIC MELANOMA: ABSTRACTS (3/4)

EPICS

- **10006:** Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating

RELAPSED/REFRACTORY METASTATIC MELANOMA: ABSTRACTS (4/4)

EPICS

- **10045:** Response to immune checkpoint inhibitor (ICI) rechallenge after high-grade immune related

RELAPSED/REFRACTORY METASTATIC MELANOMA: DISCUSSION (1/3)

EPICS

- The data regarding ipilimumab plus an anti–PD-1 antibody in patients with progression on an anti–

RELAPSED/REFRACTORY METASTATIC MELANOMA: DISCUSSION (2/3)

- The response and durability data with lifileucel were considered very encouraging, particularly in

RELAPSED/REFRACTORY METASTATIC MELANOMA: DISCUSSION (3/3)

EPICS

- The Shah et al data on rechallenging patients who have experienced high-grade irAEs with an

APTITUDE HEALTH®

EPICS

Immunotherapy for Metastatic Melanoma

MICHAEL ATKINS, MD

GEORGETOWN-LOMBARDI COMPREHENSIVE CANCER CENTER

WASHINGTON, DC, USA

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (1/7)

EPICS

- **10008:** Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (2/7)

EPICS

- **10007:** Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (3/7)

EPICS

- **10003:** A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (4/7)

EPICS

- **10009:** Integrative tumor and immune cell multi-omic analyses to predict melanoma response to

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (5/7)

EPICS

- **10010:** Using machine learning to predict immunotherapy response in advanced melanoma.

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (6/7)

EPICS

- **10011:** Autoantibodies as predictors for survival and immune-related adverse events in checkpoint

IMMUNOTHERAPY FOR METASTATIC MELANOMA: ABSTRACTS (7/7)

EPICS

- **10030:** Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed

IMMUNOTHERAPY FOR METASTATIC MELANOMA: DISCUSSION (1/3)

EPICS

- Experts believe that it will be possible to reduce the number of cycles of ipilimumab plus an anti–

IMMUNOTHERAPY FOR METASTATIC MELANOMA: DISCUSSION (2/3)

EPICS

- Ipilimumab plus an anti–PD-1 antibody is considered the most efficacious therapy currently

IMMUNOTHERAPY FOR METASTATIC MELANOMA: DISCUSSION (3/3)

EPICS

- While the emerging data with novel biomarkers is considered interesting and encouraging, none

APTITUDE HEALTH®

EPICS

BRAF-Mutated Metastatic Melanoma

JAMES LARKIN, MD
THE ROYAL MARSDEN
LONDON, UK

REINHARD DUMMER, MD
UNIVERSITY HOSPITAL OF ZURICH
ZURICH, SWITZERLAND

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (1/7)

EPICS

- **10001:** Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (2/7)

EPICS

- **10012:** Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (3/7)

EPICS

- **10022:** A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (4/7)

EPICS

- **10039:** Association of prior immune checkpoint blockade (ICB) with longer progression-free survival

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (5/7)

EPICS

- **10021:** The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short-term

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (6/7)

EPICS

- **10023:** Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or

BRAF-MUTATED METASTATIC MELANOMA: ABSTRACTS (7/7)

EPICS

- **10028:** The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in

BRAF-MUTATED METASTATIC MELANOMA: DISCUSSION (1/3)

EPICS

- Experts expressed some surprise that with longer-term follow-up of the COMBI-AD trial, the survival

BRAF-MUTATED METASTATIC MELANOMA: DISCUSSION (2/3)

EPICS

- The optimal strategy for using BRAF/MEK inhibition and immune checkpoint inhibition (triplet

BRAF-MUTATED METASTATIC MELANOMA: DISCUSSION (3/3)

EPICS

- Unfortunately, the pilot study investigating the use of NGS-detected molecular alterations to direct

APTITUDE HEALTH®

US Headquarters
5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters
Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

aptitude-health.com